Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model

dc.contributor.authorArias, Cesar A.
dc.contributor.authorSingh, Kavindra V.
dc.contributor.authorPanesso, Diana
dc.contributor.authorMurray, Barbara E.
dc.contributor.orcidPanesso, Diana [0000-0002-4049-9702]
dc.date.accessioned2020-12-03T19:31:04Z
dc.date.available2020-12-03T19:31:04Z
dc.date.issued2007
dc.description.abstractenglishCeftobiprole is a novel broad-spectrum cephalosporin with good in vitro activity against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. The objective of this study was to assess the in vivo activity of ceftobiprole against four strains of E. faecalis, including β-lactamase- producing (Bla+) and vancomycin-resistant strains. Mice were infected intraperitoneally with strains of E. faecalis: (i) the Bla+ strain HH22; (ii) two vancomycin-resistant strains (TX2484 and V583); and (iii) OG1RF (a laboratory strain), using 10 × the LD50 for each strain. Ceftobiprole doses of 25, 12.5 and 6.25 mg/kg (single doses) and ampicillin 50, 25, 12.5 and 6.25 mg/kg (single and double doses) were administered subcutaneously immediately after bacterial challenge and mice were monitored for 96 h. All four E. faecalis had ceftobiprole MICs ≤0.5 mg/L. Despite being susceptible in vitro at the standard inoculum, ampicillin (single and double doses) did not protect mice against intraperitoneal challenge with Bla+ E. faecalis HH22, with a 50% protective dose (PD50) of >100 mg/kg, whereas ceftobiprole was protective (PD50 of 2 mg/kg). Ceftobiprole PD50s for vancomycin-resistant isolates TX2484 and V583 were 7.7 and 5.2 mg/kg, respectively, similar to those of single dose ampicillin (12.5 and 16.4 mg/kg, respectively). For OG1RF, both ampicillin and ceftobiprole protected all mice at doses of 25 and 12.5 mg/kg, respectively, with a PD50 of 4.2 and 8 mg/kg for ceftobiprole and ampicillin, respectively. Ceftobiprole had comparable in vivo activity to that of ampicillin against vancomycin-resistant and ampicillin-susceptible strains of E. faecalis in the mouse peritonitis model. Ceftobiprole was superior in vivo to ampicillin against the Bla+ strain HH22. Our data support the further study of ceftobiprole as a therapeutic agent in humans infected with E. faecalis.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1093/jac/dkm237
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1460-2091
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/5169
dc.language.isoeng
dc.publisher.journalJournal of Antimicrobial Chemotherapyspa
dc.relation.ispartofseriesJournal of Antimicrobial Chemotherapy, 1460-2091, Vol. 60, Nro. 3, 2007 p. 594-598spa
dc.relation.urihttps://academic.oup.com/jac/article/60/3/594/734011
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2007
dc.rights.localAcceso abiertospa
dc.subject.keywordsEnterococcispa
dc.subject.keywordsCephalosporinsspa
dc.subject.keywordsAnimal modelspa
dc.titleEvaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis modelspa
dc.title.translatedEvaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis modelspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Arias_Cesar_A._2007.pdf
Tamaño:
167.14 KB
Formato:
Adobe Portable Document Format
Descripción:
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:

Colecciones